Aarti Drugs
Aarti Drugs Limited, commonly referred to as Aarti Drugs, is a prominent player in the pharmaceutical industry, headquartered in Mumbai, India. Established in 1984, the company has made significant strides in the production of active pharmaceutical ingredients (APIs) and formulations, catering to both domestic and international markets. With a diverse portfolio that includes anti-infectives, analgesics, and cardiovascular medications, Aarti Drugs stands out for its commitment to quality and innovation. The company has achieved several milestones, including regulatory approvals from major global health authorities, which solidify its market position. Recognised for its robust manufacturing capabilities and a strong emphasis on research and development, Aarti Drugs continues to contribute to the healthcare sector, ensuring the availability of essential medicines worldwide.
DitchCarbon Score
How does Aarti Drugs's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Aarti Drugs's score of 24 is higher than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Aarti Drugs's reported carbon emissions
In 2024, Aarti Drugs reported total carbon emissions of approximately 54,834,000 kg CO2e for Scope 1 and about 80,250,000 kg CO2e for Scope 2, resulting in a combined total of approximately 135,084,000 kg CO2e. This marks a slight increase in Scope 2 emissions compared to 2023, where they recorded about 76,414,000 kg CO2e for Scope 2 and 54,834,000 kg CO2e for Scope 1, totalling approximately 135,084,000 kg CO2e. Aarti Drugs has set ambitious climate commitments, aiming to reduce both Scope 1 and Scope 2 emissions by 50% by 2030, using 2020 as the baseline year. This commitment reflects the company's proactive approach to addressing climate change and reducing its carbon footprint across all operational sites. The company has not disclosed any Scope 3 emissions data, indicating a focus on direct and indirect emissions from its own operations and energy use. Aarti Drugs continues to monitor and report its emissions, striving for transparency and accountability in its sustainability efforts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 84,380,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 104,966,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Aarti Drugs is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
